Introduction: Perforation of the uterus or fallopian tube during microinsert placement, with subsequent migration of the microinsert into the abdominopelvic cavity, is a known complication.
INTRODUCTION
Female sterilization is the most common method of contraception worldwide, being used by 19% of female persons aged 15 to 49 years who are currently married or in a union. 1 Permanent sterilization methods prevent pregnancy by disrupting fallopian tube patency and include techniques that involve surgical cutting, mechanical blockage, electrical coagulation, or blocking the fallopian tubes with chemicals and microinserts that induce fibrosis. 2 The Essure system (Conceptus, Mountain View, California) uses microinserts that are placed by hysteroscopy into the proximal portions of each fallopian tube, where they induce fibrotic tubal occlusion. 3, 4 Despite its safety and technical feasibility, complications are known to occur in up to 3% of women undergoing this method of permanent sterilization. 4 Perforation of the uterus or fallopian tube during microinsert placement, with subsequent migration of the microinsert, is a well-documented complication that may or may not cause symptoms. 4 -6 We searched PubMed, Ovid, Embase, and Google Scholar for all English-language articles published between 2000 and 2013 using the following search terms: Essure, small bowel, complications, and migration. Our search found 2 cases of small-bowel obstruction or perforation related to Essure microinserts. 5, 6 On the basis of our search, this report represents the first case of asymptomatic incorporation of an Essure microinsert in the serosa of the distal small bowel.
use of a 5.5-mm 30°hysteroscope, a grossly normal intrauterine cavity and bilateral ostia were visualized. The Essure microinserts were placed in the proximal portion of both fallopian tubes without difficulty. At the end of the procedure, 3 coils were noted at the right ostium and 7 coils at the left ostium.
The patient returned 4 months later for hysterosalpingography (HSG) to confirm tubal occlusion. At this visit, she denied abdominal or pelvic pain. After intrauterine injection of radiographic dye, the left microinsert was found to be in an anatomically correct position, with blockage of dye through the fallopian tube. The right microinsert, however, appeared to be in two places. One part of the microinsert was identified in the right cornu of the uterus, whereas the other part was in an unspecified area in the pelvic cavity (Figure 1 ). Free spillage of radiographic dye was noted through the right fallopian tube (Figure 2) . The findings were reviewed in detail with the patient.
The patient returned to the office to discuss other methods of sterilization. On the basis of this discussion, she elected to undergo tubal fulguration through the laparoscopic approach. A 5-mm umbilical port was placed, and a 30°lapa-roscope was used to perform a primary survey of the pelvic anatomy; no gross abnormalities were noted. On closer inspection of the right cornu of the uterus, a projecting serosalized fragment of the microinsert was noted (Figure 3) . The second fragment of the microinsert was found incorpo- rated in the serosa of the distal ileum (Figure 4) . The microinsert did not move with peristalsis, and there was no evidence of bowel perforation, strangulation, inflammation, or dilatation. Furthermore, no blood or pus was noted in the abdominopelvic cavity, with the remainder of the bowel appearing grossly normal. An intraoperative consultation with the colorectal surgery team was requested, and a detailed discussion about removal of the microinsert and a possible bowel resection ensued. On the basis of the recommendations made by the colorectal surgeons, as well as the low likelihood of further migration of the microinsert fragment, we decided to leave both fragments of the microinsert as is. We subsequently performed tubal fulguration with bipolar cautery for sterilization. The patient tolerated the procedure well and was informed of all intraoperative findings. She made an uneventful recovery and had no complaints during her subsequent postoperative visits 2 weeks later. During her annual gynecologic visit 1 year later, the patient denied new clinical symptoms.
DISCUSSION
After its approval by the Food and Drug Administration in 2002, the Essure system has become an increasingly popular method of female sterilization worldwide. 6, 7 The Essure system comprises expanding microinserts that are placed within the proximal portions of the fallopian tubes under hysteroscopic visualization. 3 The microinserts consist of a nickel-titanium alloy outer coil, as well as a flexible stainless steel inner coil that is surrounded by white polyethylene terephthalate fibers, that incites benign tissue ingrowth by a fibrotic reaction when in contact with tissue. 8 Over a 3-month period, the fibrotic reaction leads to tubal occlusion. In addition to the reported efficacy of 99.87%, this mode of sterilization can be performed in the office in a safe and technically feasible manner, with a successful placement rate of 94% during the first attempt. 9, 10 Despite these advantages, complications associated with microinsert placement do occur, the most serious of which include perforation and microinsert migration. Perforation of the uterus or fallopian tube at the time of microinsert placement occurs in up to ϳ2% of cases. 11 Possible causes of perforation include poor visualization during device placement, tubal spasm, or uterine and tubal abnormalities. 5, 11 In these settings the microinsert is less likely to track along the fallopian tube, thereby increasing the likelihood for perforation. 6, 11 Migration of microinserts after placement is extremely rare, with an estimated incidence of 0.1%. 11 Although current data indicate that long-term adverse events are not associated with microinsert perforation and migration, microinsert-induced bowel perforation and bowel obstruction have been described in the medical literature. 4 -6 Mantel et al 5 recently published a case of small-bowel obstruction and perforation occurring 1 month after Essure microinsert placement. At laparotomy, the microinsert that had migrated was found ensnaring the terminal ileum, where it had caused strangulation and local perforation of the bowel wall. After removal of the device, an ileocecal resection with side-to-side ileocolostomy was performed. Similarly, Belotte et al 6 presented a case of small-bowel obstruction related to an Essure microinsert that had migrated 1 month after placement. In this case laparoscopy showed that the microinsert was adherent to the lateral aspect of the mid ileum, which was the focal point of obstruction because of adhesions. The patient underwent adhesiolysis, left salpingectomy, appendectomy, and removal of the microinsert that had migrated. In both cases perforation at the time of microinsert placement was hypothesized to be the reason for abdominal migration of the device.
Consistent with the aforementioned cases, our patient underwent seemingly uncomplicated placement of Essure microinserts. As in the other cases, we postulate that perforation of the uterus or fallopian tube occurred at the time of microinsert placement. In contrast to the other cases, however, our patient remained asymptomatic despite incorporation of the microinsert into the serosa of the distal ileum. We suspect that after perforation of the uterus or fallopian tube, breakage and subsequent abdominal migration of the microinsert occurred. It is also possible that the fragmented microinsert may represent a device failure. Although the reasons for breakage of the microinsert remain uncertain, we postulate that the fragment of the microinsert that had migrated may have settled on the distal ileum, where it induced a fibrotic reaction to become incorporated within the serosa. Because the microinsert did not strangle or directly damage the small bowel, the patient remained asymptomatic. Belotte et al 6 suggest removal of the microinsert from the peritoneal cavity as soon as misplacement is diagnosed, in light of peritoneal adhesions and the possibility of small-bowel obstruction. Although we strongly considered this management option in our patient, we were dissuaded by our colorectal surgery colleagues because of the patient's lack of symptoms and the lack of detailed informed consent about bowel resection that may have been necessary to remove the microinsert.
